Pfizer Investor Presentation — July 2021

Document content

Breakthroughs that change patients' lives ®

July28, 2021Second Quarter 2021

Earnings TeleconferenceIntroduction

Senior Vice President,

Chief Investor Relations Officer3

Second Quarter 2021 EarningsForward -Looking Statements and Non -GAAP Financial Information

lOur discussions during this conference call will include forward -looking statements that are subject to substantial risks and uncertainties that could cause actual

results to differ materially from those expressed or implied by such statements. We include forward -looking statements about, am ong other topics, our

anticipated operating and financial performance, reorganizations, business plans and prospects, expectations for our product pipeline, in -line products and

product candidates, including anticipated regulatory submissions, data read -outs, study starts, approvals, clinical trial result s and other developing data that

become available, revenue contribution, growth, performance, timing of exclusivity and potential benefits, strategic reviews, capital allocation objectives,

dividends and share repurchases, plans for and prospects of our acquisitions, dispositions and other business development act ivities, and our ability to

successfully capitalize on these opportunities, manufacturing and product supply, our efforts to respond to COVID -19, including the Pfizer -BioNTech COVID -19

vaccine (BNT162b2) and our investigational protease inhibitors, and our expectations regarding the impact of COVID -19 on our bus iness, operations and

financial results. Among other things, statements regarding revenue and earnings per share growth; the development or commerc ialpotential of our product

pipeline, in -line products, product candidates and additional indications, including expected clinical trial protocols, the timi ng of the initiation and progress of